SCHEMBL4528181

SCHEMBL4528181

CCN(CC)C(=O)COc1ccc(CC2CCN([C@H]3CCc4ccccc43)C2=O)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
GPR84 Q9NQS5 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SIGMAR1 Q99720 1/20 0.35
TRPM8 Q7Z2W7 3/20 0.35
MTNR1B P49286 3/20 0.35
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CYP27A1 Q02318 1/20 0.34
CYP24A1 Q07973 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510366 0.84 KDM4E (0.46) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4514845 0.84 KDM4E (0.46) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4521693 0.84 KDM4E (0.41) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4506063 0.83 TSHR (0.38) PRMT5WDR77ALDH1A1MEN1KMT2A
SCHEMBL4526129 0.82 SIGMAR1 (0.42) SMN1; SMN2KDM4EALDH1A1MEN1KMT2A
SCHEMBL4510855 0.79 ALDH1A1 (0.39) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4526694 0.79 KDM4E (0.44) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4510847 0.79 SMN1; SMN2 (0.52) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4521423 0.78 KDM4E (0.38) SMN1; SMN2KDM4EALDH1A1MEN1MAPT
SCHEMBL4524149 0.78 KDM4E (0.43) SMN1; SMN2KDM4EALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 PRMT5 1436/4885WDR77 1740/4885SMN1; SMN2 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.